Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effective May 1, 2026.
Luigi La Corte will join Galderma on April 1 to begin a smooth and orderly transition with Thomas Dittrich, who has served as CFO of Galderma since October 2019. As previously announced, Thomas will remain with the company through Q2 2026 to ensure a seamless transition before pursuing another senior executive opportunity outside the organization.
“Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership in dermatology. I would also like to thank Thomas for his commitment to ensuring a seamless transition and his many contributions to Galderma during his time with the company.” FLEMMING ØRNSKOV, M.D., MPH CHIEF EXECUTIVE OFFICER GALDERMA |
Luigi La Corte brings more than 30 years of international financial leadership experience across healthcare and consumer businesses. Most recently, he served as CFO of the global pharmaceutical company Recordati S.p.A from 2019 – 2025, where he was responsible for Group Finance, Investor Relations, Sustainability and Information Systems. He was appointed to Recordati's Board of Directors in 2022, a position he continues to hold.
Previously, Luigi La Corte held a range of senior finance leadership roles within the pharmaceutical sector, including positions at GlaxoSmithKline, AstraZeneca and Alliance Unichem, and served as CFO at Pladis Food Group. Earlier in his career he also worked for Bain & Company, PepsiCo and Procter & Gamble. An Italian national, he holds a Master in Economics from Luiss University and is a Fellow of the Chartered Institute of Management Accountants.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
Forward-looking statements
Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.
HCL Foundation继续致力于改善农村生活
Sirion荣获亚太区创新类别的2024年Oracle
CorFlow Therapeutics AG完成4400
Lenovo在“2024年Lenovo创新世界大会”上发布
泰雷兹向澳大利亚昆士兰州提供数字执照解决方
Takeda Announces Publication
Hologic Partners With th
跨国顶尖律所ROSEN鼓励 Sesen Bio
益博睿发布新版全球报告,概述其环境、
“传奇之上”带来无限精彩 澳门上葡京综合度
无棣县开展城市养犬管理集中宣传活动
给所有玩家的选择!AMD于2019 E3展公布领先的P
Yugabyte宣布举办首届分布式SQL亚洲峰会
COPC 宣布客户服务历程咨询计划
穆迪分析新的早期预警系统可帮助更快识别信贷
联想第二季度业绩创纪录 所有业务实现强劲增
ESI Group推出“无会议日”来保护雇员的工作生活
未来两年项目融资使用量将激增
春城晚报(开屏新闻)生活节“情绪咖啡亭”项
DRDM打造专业护肤顾问体系为每一位用户定制专
IQM Quantum Computers公
蒙商出海考察“走出去”“引进来”,探索践行
芯原助力蓝洋智能部署基于Chiplet架构的芯片产
中国当代最具升值潜力艺术家——黄名芊专题报